August 23, 2024 07:00 AM EDT
Peer Review

Gen­mab makes two C-suite ad­di­tions as COO leaves; James Sabry leads a re­vamped sup­port­ing cast at Bio­Marin

Alex Hoffman

Senior Editor

Kathy Wong

Editor

→ There are sub­stan­tial lead­er­ship changes at Gen­mab, start­ing with the de­par­ture of COO An­tho­ny Manci­ni. Peer Re­view

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Seres' mi­cro­bio­me ther­a­py re­duces in­fec­tions in stem cell trans­plant pa­tients, but next steps are un­clear

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Charles Riv­er to lay off 3% of staffers as it stream­lines spend­ing

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

Noom of­fers com­pound­ed GLP-1 drugs, promis­es pa­tients can quit and keep weight off

FDA should em­brace new ways of eval­u­at­ing rare dis­ease drugs, re­port ar­gues

A service from the Financial Times